Antibody Response to COVID-19 Vaccines in Liver Disease Patients
Antibody Response to COVID-19 Vaccines in Liver Disease Patients
Currently the Pfizer-Biontech (mRNA), Sinovac (inactivated virus) and Astrazeneca-Oxford
 (adenovirus-vector) COVID-19 vaccines are available for vaccination in HK. The American
 Association of Liver Disease has recently published consensus statements for COVID-19
 vaccination in subjects with chronic liver disease (CLD). Patients with CLD have dysregulated
 innate and adaptive immune response that may be associated with vaccine hypo-responsiveness
 and there are no data as to whether these patients may respond differently to the various
 vaccines. The Humanity and Health Medical Center (HHMC) is an active participant of the HK
 government COVID-19 vaccination programs and patients with CLD follow-up at HHMC will have
 access to the three different vaccines. The aim of this prospective study is to compare the
 antibody response of CLD subjects to the Pfizer-Biontech (mRNA), Sinovac (inactivated virus)
 and Astrazeneca-Oxford (adenovirus-vector) COVID-19 vaccines.
Inclusion Criteria:

 1. Subjects with chronic liver disease (CLD) at the Humanity and Health Medical Group and
 eligible for the HK government vaccination programme;

 2. Able to understand and sign informed consent.;

 3. Underlying CLD- defined as patients with chronic hepatitis B or C infections, liver
 cirrhosis, metabolic associated liver disease, hepatocellular carcinoma, alcoholic
 liver disease, autoimmune hepatitis, hemochrombtosis.

 Exclusion Criteria:

 1. Patients contraindicated for the COVID -19 Vaccination Program due to uncontrolled
 co-morbitities;

 2. Past allergies to other vaccines;

 3. Pregnant subjects.